86367-90-0|Cholecystokinin (27-32)-amide|(5S,11S,14S,17S)-11-((1H-indol-3-yl)methyl)-5-((S)-2-amino-3-(4-(sulfooxy)phenyl)propanamido)-17-carbamoyl-14-(2-(methylthio)ethyl)-6,9,12,15-tetraoxo-2-thia-7,10,13,16-tetraazanonadecan-19-oic acid|-范德生物科技公司

Cholecystokinin (27-32)-amide

NMR下载 COA and HPLC MSDS下载
names：
(5S,11S,14S,17S)-11-((1H-indol-3-yl)methyl)-5-((S)-2-amino-3-(4-(sulfooxy)phenyl)propanamido)-17-carbamoyl-14-(2-(methylthio)ethyl)-6,9,12,15-tetraoxo-2-thia-7,10,13,16-tetraazanonadecan-19-oic acid
CAS号：
86367-90-0
MDL Number：
MF(分子式)： C36H48N8O12S3 MW(分子量)： 881
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Cholecystokinin (27-32)-amide
英文别名	Cholecystokinin (27-32)-amide; Cholecystokinin (27-32)-NH2;
CAS号	86367-90-0
Inchi	InChI=1S/C36H48N8O12S3/c1-57-13-11-26(42-33(49)24(37)15-20-7-9-22(10-8-20)56-59(53,54)55)34(50)40-19-30(45)41-29(16-21-18-39-25-6-4-3-5-23(21)25)36(52)43-27(12-14-58-2)35(51)44-28(32(38)48)17-31(46)47/h3-10,18,24,26-29,39H,11-17,19,37H2,1-2H3,(H2,38,48)(H,40,50)(H,41,45)(H,42,49)(H,43,52)(H,44,51)(H,46,47)(H,53,54,55)/t24-,26-,27-,28-,29-/m0/s1
InchiKey	WUUXPYBWGKLWBA-CISYKLKFSA-N
分子式 Formula	C36H48N8O12S3
分子量 Molecular Weight	881
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Cholecystokinin (27-32)-amide(CAS:86367-90-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Cholecystokinin (27-32)-amide is a CCK C-terminal heptapeptide minus COOH-terminal Phe residue; CCK receptor antagonist.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Tarasova NI, Stauber RH, Choi JK, Hudson EA, Czerwinski G, Miller JL, Pavlakis GN, Michejda CJ, Wank SA. Visualization of G protein-coupled receptor trafficking with the aid of the green fluorescent protein. Endocytosis and recycling of cholecystokinin receptor type A. J Biol Chem. 1997 Jun 6;272(23):14817-24. PubMed PMID: 9169450.

[2]Staley J, Jensen RT, Moody TW. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells. Peptides. 1990 Sep-Oct;11(5):1033-6. PubMed PMID: 2178246.

[3] Menozzi D, Gardner JD, Jensen RT, Maton PN. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Am J Physiol. 1989 Jul;257(1 Pt 1):G73-9. PubMed PMID: 2473654.

[4] Barone FC, Bondinell WE, Labosh TJ, White RF, Ormsbee HS 3rd. Cholecystokinin stimulates neuronal receptors to produce contraction of the canine colon. Life Sci. 1989;44(8):533-42. PubMed PMID: 2927258.

[5] Vinayek R, Jensen RT, Gardner JD. Role of sulfate ester in influencing biologic activity of cholecystokinin-related peptides. Am J Physiol. 1987 Feb;252(2 Pt 1):G178-81. PubMed PMID: 2435164.

6: Yoder DG, Moody TW. High affinity binding of cholecystokinin to small cell lung cancer cells. Peptides. 1987 Jan-Feb;8(1):103-7. PubMed PMID: 3033616.7: Otsuki M, Okabayashi Y, Ohki A, Oka T, Fujii M, Nakamura T, Sugiura N, Yanaihara N, Baba S. Action of cholecystokinin analogues on exocrine and endocrine rat pancreas. Am J Physiol. 1986 Apr;250(4 Pt 1):G405-11. PubMed PMID: 2421584.8: Vigna SR, Szecòwka J, Williams JA. Do antagonists of pancreatic cholecystokinin receptors interact with central nervous system cholecystokinin receptors? Brain Res. 1985 Sep 23;343(2):394-7. PubMed PMID: 2996701.9: Briet C, Aumelas A, Martinez J. Synthesis of Z-CCK-27-32-NH2, Z-Tyr(SO-3)-Met-Gly-Trp-Met-Asp-NH2, a cholecystokinin receptor antagonist and an inhibitor of gastrin-induced acid secretion. Int J Pept Protein Res. 1985 Sep;26(3):294-8. PubMed PMID: 2997059.10: Martinez J, Bali JP. A new class of potent gastrin antagonists. Regul Pept. 1984 Nov;9(4):259-62. PubMed PMID: 6097950.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开